To learn more about Selective Internal Radiation Therapy (SIRT) for treating liver cancer and the unique benefits of our products, visit our patient information website.
Q-Suite™ is software for dosimetric verification of Ho-166 SIRT. A workflow-based user interface makes Q-Suite™ easy to learn and use.
The Quirem team will attend CIRSE in Barcelona from September 7-11 2019.
SIRT in three steps
Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to improve patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in three simple steps:
News and events
The first QuiremScout® cases have been successfully performed by clinical teams in Dresden and Pisa last week. We congratulate the clinical teams, and everyone involved! QuiremScout® is the first and only CE-marked SIRT work-up product
We are pleased to announce that the Radboudumc in Nijmegen has treated its first patient with QuiremSpheres®. This milestone has been made possible by an interdisciplinary team, consisting of Dr. Marcel Janssen (Nuclear Medicine physician),
What our customers say